Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$389.28

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $389.28 8

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $389.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $20.3411/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938955291 CMS
IDORSIA PHARMACEUTICALS US INC $125.0011/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951474987 CMS
Janssen Biotech, Inc. $23.2610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885758267 CMS
Corium, LLC $122.4009/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924876759 CMS
Janssen Biotech, Inc. $17.9409/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885758261 CMS
Journey Medical Corporation $15.8208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924778721 CMS
Lilly USA, LLC $28.5507/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918158195 CMS
Regeneron Healthcare Solutions, Inc. $35.9706/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927483773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

191 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $75.00 12/29/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY LL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889827193
Principal investigator 1 Incyte Corporation $5,171.85 12/29/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243433
Principal investigator 1 Incyte Corporation $6,085.00 12/16/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243467
Principal investigator 1 Incyte Corporation $50.00 12/09/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243437
Principal investigator 1 Incyte Corporation $180.00 12/09/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243445
Principal investigator 1 Incyte Corporation $400.00 12/09/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243447
Principal investigator 1 Incyte Corporation $173.00 12/09/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243461
Principal investigator 1 Incyte Corporation $172.00 12/09/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243463
Principal investigator 1 Incyte Corporation $1,190.00 12/09/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243465
Principal investigator 1 PFIZER INC. $1,856.25 12/06/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949734901
Principal investigator 1 Incyte Corporation $46,546.65 12/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243429
Principal investigator 1 Incyte Corporation $857.00 12/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243431
Principal investigator 1 Incyte Corporation $345.00 12/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243435
Principal investigator 1 Incyte Corporation $80.00 11/21/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243443
Principal investigator 1 Incyte Corporation $173.00 11/21/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243457
Principal investigator 1 Incyte Corporation $170.00 11/21/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243459
Principal investigator 1 Incyte Corporation $8,435.00 11/18/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243455
Principal investigator 1 Incyte Corporation $1,032.00 11/10/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243423
Principal investigator 1 Incyte Corporation $8,657.95 11/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243425
Principal investigator 1 Incyte Corporation $2,138.00 11/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243427
Principal investigator 1 Incyte Corporation $60.00 11/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243439
Principal investigator 1 Incyte Corporation $80.00 11/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243441
Principal investigator 1 Incyte Corporation $48.75 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243373
Principal investigator 1 Incyte Corporation $102.10 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243375
Principal investigator 1 Incyte Corporation $73.17 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243377
Principal investigator 1 Incyte Corporation $30.63 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243379
Principal investigator 1 Incyte Corporation $37.53 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243381
Principal investigator 1 Incyte Corporation $68.52 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243383
Principal investigator 1 Incyte Corporation $205.50 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243385
Principal investigator 1 Incyte Corporation $3.24 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243387
Principal investigator 1 Incyte Corporation $1.65 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243389
Principal investigator 1 Incyte Corporation $188.85 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243391
Principal investigator 1 Incyte Corporation $48.75 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243395
Principal investigator 1 Incyte Corporation $37.53 11/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243397
Principal investigator 1 Incyte Corporation $400.00 10/26/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243449
Principal investigator 1 Incyte Corporation $800.00 10/26/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243453
Principal investigator 1 PFIZER INC. $3,056.25 10/22/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949738985
Principal investigator 1 Incyte Corporation $8,320.00 10/21/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243451
Principal investigator 1 Incyte Corporation $1,246.00 10/07/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243421
Principal investigator 1 Incyte Corporation $37.53 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243357
Principal investigator 1 Incyte Corporation $68.52 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243359
Principal investigator 1 Incyte Corporation $48.75 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243361
Principal investigator 1 Incyte Corporation $73.17 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243363
Principal investigator 1 Incyte Corporation $30.63 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243365
Principal investigator 1 Incyte Corporation $3.24 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243367
Principal investigator 1 Incyte Corporation $151.08 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243369
Principal investigator 1 Incyte Corporation $1.65 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243371
Principal investigator 1 Incyte Corporation $37.53 10/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243393
Principal investigator 1 PFIZER INC. $1,856.25 09/22/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949743329
Principal investigator 1 Incyte Corporation $1,559.00 09/15/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243417
Principal investigator 1 ABBVIE INC. $75.00 09/08/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY LL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889810429
Principal investigator 1 Incyte Corporation $2,645.00 09/08/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243413
Principal investigator 1 Incyte Corporation $350.00 09/08/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243415
Principal investigator 1 ABBVIE INC. $1,698.68 09/07/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889808757
Principal investigator 1 Incyte Corporation $2,006.55 09/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243411
Principal investigator 1 Incyte Corporation $1,159.00 08/19/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243409
Principal investigator 1 ABBVIE INC. $650.75 08/18/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY LL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889807009
Principal investigator 1 ABBVIE INC. $1,698.68 08/11/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889805731
Principal investigator 1 PFIZER INC. $2,656.25 08/09/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949743183
Principal investigator 1 Incyte Corporation $2,651.40 08/05/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243405
Principal investigator 1 Incyte Corporation $166.00 08/05/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243407
Principal investigator 1 ABBVIE INC. $4,550.00 07/15/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY LL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889801239
Principal investigator 1 ABBVIE INC. $9,500.00 07/15/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY LL
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 889801313
Principal investigator 1 Incyte Corporation $40.00 07/15/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243403
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,232.00 07/12/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933393469
Principal investigator 1 Eli Lilly and Company $4,492.00 07/12/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917819835
Principal investigator 1 ABBVIE INC. $50.00 07/11/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889799671
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,282.00 07/11/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY DBA OLYMPIAN CLINICAL RESEARCH
A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder No dispute reported 06/30/2026 933393177
Principal investigator 1 Incyte Corporation $642.00 07/08/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243419
Principal investigator 1 PFIZER INC. $474.75 07/08/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735553
Principal investigator 1 Incyte Corporation $1,961.55 06/29/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243399
Principal investigator 1 Incyte Corporation $5,182.58 06/29/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243401
Principal investigator 1 PFIZER INC. $2,448.50 06/24/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735371
Principal investigator 1 ABBVIE INC. $3,300.00 06/23/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889796711
Principal investigator 1 Incyte Corporation $3,451.00 06/15/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243355
Principal investigator 1 ABBVIE INC. $582.54 06/14/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889795105
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $550.00 06/10/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933390065
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,095.00 06/06/2022 Non-covered Recipient Entity
Olympian Clinical Research - South Tampa Office
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 933191667
Principal investigator 1 Incyte Corporation $7,392.60 06/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243349
Principal investigator 1 Incyte Corporation $6,699.63 06/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243351
Principal investigator 1 Incyte Corporation $5,177.44 06/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243353
Principal investigator 1 Incyte Corporation $5,000.00 05/20/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243337
Principal investigator 1 Incyte Corporation $50.00 05/19/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243329
Principal investigator 1 ABBVIE INC. $4,148.12 05/12/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889791129
Principal investigator 1 Incyte Corporation $1,248.60 05/12/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243327
Principal investigator 1 Incyte Corporation $241.00 05/12/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243331
Principal investigator 1 Incyte Corporation $1,826.55 05/06/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243325
Principal investigator 1 Incyte Corporation $7,400.00 05/06/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243333
Principal investigator 1 PFIZER INC. $1,856.25 05/06/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735201
Principal investigator 1 Incyte Corporation $65.00 05/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243343
Principal investigator 1 Incyte Corporation $50.04 05/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243345
Principal investigator 1 Incyte Corporation $100.72 05/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243347
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,725.00 04/27/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933385857
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,275.00 04/27/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933385865
Principal investigator 1 ABBVIE INC. $75.00 04/26/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889788715
Principal investigator 1 Incyte Corporation $582.00 04/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243283
Principal investigator 1 Incyte Corporation $136.00 04/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243285
Principal investigator 1 Incyte Corporation $301.00 04/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243287
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,089.82 04/11/2022 Non-covered Recipient Entity
Olympian Clinical Research
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 933188501
Principal investigator 1 Incyte Corporation $86.00 04/08/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243281
Principal investigator 1 ABBVIE INC. $1,442.86 04/05/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889783623
Principal investigator 1 Incyte Corporation $800.00 04/04/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243335
Principal investigator 1 Incyte Corporation $50.00 04/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243275
Principal investigator 1 Incyte Corporation $136.00 04/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243277
Principal investigator 1 Incyte Corporation $1,356.80 04/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243279
Principal investigator 1 Incyte Corporation $50.04 04/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243339
Principal investigator 1 Incyte Corporation $65.00 04/01/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243341
Principal investigator 1 ABBVIE INC. $585.42 03/30/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889782767
Principal investigator 1 Incyte Corporation $10,968.85 03/30/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243319
Principal investigator 1 Incyte Corporation $358.00 03/30/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243321
Principal investigator 1 Incyte Corporation $13,805.96 03/30/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243323
Principal investigator 1 ABBVIE INC. $66.24 03/23/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889782345
Principal investigator 1 Incyte Corporation $642.00 03/23/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243209
Principal investigator 1 Incyte Corporation $926.00 03/23/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243317
Principal investigator 1 PFIZER INC. $1,856.25 03/23/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735699
Principal investigator 1 ABBVIE INC. $725.96 03/17/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889781887
Principal investigator 1 ABBVIE INC. $120.00 03/16/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889781217
Principal investigator 1 ABBVIE INC. $1,875.00 03/10/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889780563
Principal investigator 1 Incyte Corporation $1,081.70 03/10/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243313
Principal investigator 1 Incyte Corporation $1,413.70 03/10/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243315
Principal investigator 1 ABBVIE INC. $5,590.98 03/09/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889780053
Recipient Eli Lilly and Company $1,428.00 03/08/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917812611
Principal investigator 1 Incyte Corporation $450.00 03/07/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243207
Principal investigator 1 ABBVIE INC. $545.77 03/02/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 889778903
Principal investigator 1 Eli Lilly and Company $7,433.00 03/02/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO ASSESS THE IMPACT OF LEBRIKIZUMAB ON VACCINE RESPONSES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917821459
Principal investigator 1 Incyte Corporation $81.25 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243165
Principal investigator 1 Incyte Corporation $122.52 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243167
Principal investigator 1 Incyte Corporation $50.04 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243169
Principal investigator 1 Incyte Corporation $48.78 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243171
Principal investigator 1 Incyte Corporation $34.25 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243211
Principal investigator 1 Incyte Corporation $35.08 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243213
Principal investigator 1 Incyte Corporation $1.43 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243215
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243217
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243219
Principal investigator 1 Incyte Corporation $50.04 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243221
Principal investigator 1 Incyte Corporation $2.16 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243223
Principal investigator 1 Incyte Corporation $21.08 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243225
Principal investigator 1 Incyte Corporation $20.26 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243227
Principal investigator 1 Incyte Corporation $2.20 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243229
Principal investigator 1 Incyte Corporation $1.43 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243233
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243235
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243237
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243239
Principal investigator 1 Incyte Corporation $65.00 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243241
Principal investigator 1 Incyte Corporation $50.04 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243243
Principal investigator 1 Incyte Corporation $48.78 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243245
Principal investigator 1 Incyte Corporation $2.84 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243247
Principal investigator 1 Incyte Corporation $9.61 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243249
Principal investigator 1 Incyte Corporation $151.08 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243251
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243253
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243255
Principal investigator 1 Incyte Corporation $43.92 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243257
Principal investigator 1 Incyte Corporation $81.25 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243259
Principal investigator 1 Incyte Corporation $2.16 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243261
Principal investigator 1 Incyte Corporation $14.20 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243263
Principal investigator 1 Incyte Corporation $151.08 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243265
Principal investigator 1 Incyte Corporation $4,760.10 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243307
Principal investigator 1 Incyte Corporation $25,250.02 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243309
Principal investigator 1 Incyte Corporation $10,189.08 03/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243311
Principal investigator 1 PFIZER INC. $3,462.75 03/02/2022 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949736653
Principal investigator 1 Incyte Corporation $256.00 02/22/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243301
Principal investigator 1 Incyte Corporation $2,495.75 02/22/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243303
Principal investigator 1 Incyte Corporation $246.00 02/22/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243305
Principal investigator 1 Biogen, Inc. $5,412.00 02/18/2022 Non-covered Recipient Entity
Academic Alliance In Dermatology
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease or with Mild Alzheimer's Disease No dispute reported 06/30/2026 927059647
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 02/16/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A RANDOMIZED DOUBLE-BLIND PARALLEL-GROUP TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF GWP42003-P VERSUS PLACEBO AS ADJUNCTIVE THERAPY IN PARTICIPANTS WITH SCHIZOPHRENIA EXPERIENCING INADEQUATE RESPONSE TO ONGOING ANTIPSYCHOTIC TREATMENT No dispute reported 06/30/2026 950365385
Principal investigator 1 Amgen Inc. $425.00 02/15/2022 Non-covered Recipient Entity
Olympian Clinical Research
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 939281747
Principal investigator 1 ABBVIE INC. $225.00 02/10/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) No dispute reported 06/30/2026 889776797
Principal investigator 1 Incyte Corporation $264.00 02/10/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243299
Principal investigator 1 Incyte Corporation $1,248.80 02/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243295
Principal investigator 1 Incyte Corporation $4,407.30 02/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243297
Principal investigator 1 Incyte Corporation $5,918.40 02/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243289
Principal investigator 1 Incyte Corporation $272.00 02/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243291
Principal investigator 1 Incyte Corporation $18,849.10 02/02/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243293
Principal investigator 1 ABBVIE INC. $5,000.00 01/26/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) No dispute reported 06/30/2026 889774883
Principal investigator 1 ABBVIE INC. $1,550.00 01/26/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) No dispute reported 06/30/2026 889774885
Principal investigator 1 Amgen Inc. $29,279.42 01/26/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Interchangeability Study ABP 654 No dispute reported 06/30/2026 942841519
Principal investigator 1 ABBVIE INC. $44.23 01/20/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) No dispute reported 06/30/2026 889774593
Principal investigator 1 Incyte Corporation $1,510.70 01/20/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243271
Principal investigator 1 Incyte Corporation $1,015.00 01/20/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 905243273
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,083.72 01/19/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNRISE No dispute reported 06/30/2026 909386117
Principal investigator 1 ABBVIE INC. $1,905.06 01/17/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1) No dispute reported 06/30/2026 889774377
Principal investigator 1 Incyte Corporation $2,350.00 01/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243197
Principal investigator 1 Incyte Corporation $2,500.00 01/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243199
Principal investigator 1 Incyte Corporation $1,200.00 01/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243201
Principal investigator 1 Incyte Corporation $9,750.00 01/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243203
Principal investigator 1 Incyte Corporation $2,250.00 01/14/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 905243205
Principal investigator 1 Incyte Corporation $1,110.55 01/13/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 905243267
Principal investigator 1 Incyte Corporation $189.00 01/13/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 905243269
Principal investigator 1 Eli Lilly and Company $36,845.00 01/12/2022 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917820025
Principal investigator 1 Novartis Pharmaceuticals Corporation $202.75 01/11/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 909412139
Principal investigator 1 Amgen Inc. $60,104.58 01/03/2022 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Interchangeability Study ABP 654 No dispute reported 06/30/2026 942841517